Your session is about to expire
← Back to Search
Pazopanib + Bevacizumab for Kidney Cancer
Study Summary
This trial is studying the side effects and best dosage of two drugs, pazopanib hydrochloride and bevacizumab, to treat patients with metastatic kidney cancer that has not been previously treated. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Bevacizumab is a monoclonal antibody that can prevent tumor growth by blocking the ability of tumor cells to grow and spread. Giving pazopanib hydrochloride together with bevacizumab may kill more tumor
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any ongoing illnesses that would stop me from following the study's requirements.I can swallow and keep down pills.I haven't had any cancer except for skin cancer that was fully removed, in the last 3 years.I have had VEGF therapy for kidney cancer, or in phase 1, one treatment with high dose IL-2 or anti-PD-1.I haven't had major surgery in the last 28 days and don't plan any in the next 6 months.My kidney cancer has spread and was confirmed by a biopsy.I am fully active and can carry on all pre-disease activities without restriction.My kidney function is normal or meets the required levels.My heart pumps well, with an ejection fraction over 50%.I do not have brain metastases.
- Group 1: Treatment (pazopanib hydrochloride and bevacizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the scientific community's previous experience with Pazopanib Hydrochloride?
"Pazopanib Hydrochloride was first studied in the year 2004 at Memoral Sloan Kettering Basking Ridge (Follow Up Only). As of now, there have been a total of 1719 completed clinical trials. Additionally, there are currently 401 live studies, with a considerable amount of these studies taking place in Pittsburgh, Pennsylvania."
Are there several inpatient facilities conducting this research project in North America?
"There are a total of 5 sites where this clinical trial is taking place. The University of Pittsburgh Cancer Institute (UPCI) in Pittsburgh, the Medical College of Wisconsin in Milwaukee, and the Karamanos Cancer Institute in Detroit are 3 of these sites."
What purpose does Pazopanib Hydrochloride usually serve?
"Pazopanib Hydrochloride is most often used as a treatment for malignant neoplasms. However, this medication can also be effective in managing recurrent platinum sensitive primary peritoneal cancer, advanced thyroid cancer, and stage iv epithelial ovarian cancer that has had initial surgical resection."
Share this study with friends
Copy Link
Messenger